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Laboratory strains of the mouse polyoma virus differ markedly in their abilities to replicate and induce tumors in
newborn mice. Major determinants of pathogenicity lie in the sialic binding pocket of the major capsid protein Vp1 and
dictate receptor-binding properties of the virus. Substitutions at two sites in Vp1 define three prototype strains, which
vary greatly in pathogenicity. These strains replicate in a limited fashion and induce few or no tumors, cause a
disseminated infection leading to the development of multiple solid tumors, or replicate and spread acutely causing
early death. This investigation was undertaken to determine the Vp1 type(s) of new virus isolates from naturally
infected mice. Compared with laboratory strains, truly wild-type viruses are constrained with respect to their selectivity
and avidity of binding to cell receptors. Fifteen of 15 new isolates carried the Vp1 type identical to that of highly
tumorigenic laboratory strains. Upon injection into newborn laboratory mice, the new isolates induced a broad
spectrum of tumors, including ones of epithelial as well as mesenchymal origin. Though invariant in their Vp1 coding
sequences, these isolates showed considerable variation in their regulatory sequences. The common Vp1 type has two
essential features: 1) failure to recognize ‘‘pseudoreceptors’’ with branched chain sialic acids binding to which would
attenuate virus spread, and 2) maintenance of a hydrophobic contact with true receptors bearing a single sialic acid,
which retards virus spread and avoids acute and potentially lethal infection of the host. Conservation of these
receptor-binding properties under natural selection preserves the oncogenic potential of the virus. These findings
emphasize the importance of immune protection of neonates under conditions of natural transmission.
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Introduction
Interest in the murine polyoma virus (Py) grew out of its
discovery as a tumor-inducing agent in its natural host under
experimental conditions [1]. The original virus isolates were
obtained from tissues of inbred laboratory mice [2]. Plaque
puriﬁcation and molecular cloning have been used in
different laboratories to establish independent ‘‘wild-type’’
virus strains, which have been propagated in cell culture over
many years. Studies of these strains have provided a detailed
understanding of the replicative and transforming functions
of the virus [3], as well as their tumorigenic properties [4].
Laboratory strains have also been highly puriﬁed and used for
structural studies of the virus and its interaction with
receptors [5].
Cell transformation based on focus formation or growth in
soft agar has generally been accepted as the in vitro
counterpart of tumor induction in the animal. However,
assays in cell culture do not give a complete account of
functions required by the virus to replicate or induce tumors
in mice. Py mutants altered in tumor (T) antigen functions
essential for transformation may retain the ability to induce
tumors [6,7]. Moreover, different ‘‘wild-type’’ virus strains
commonly used in the laboratory, while equally efﬁcient in
transforming cells in vitro, may differ greatly in their abilities
to replicate and induce tumors in the intact host [8]. These
differences are related not to T antigen functions but rather
to receptor-binding properties of the major capsid protein
Vp1.
Structural, genetic, and biological studies have come
together to provide an understanding of how Vp1 poly-
morphisms affect virus binding to sialic acid moieties as an
essential component of cell receptors [4,5,9,10]. Single amino
acid substitutions at two positions in Vp1 alter the selectivity
and avidity of virus binding to sialic acid [5,11,12]. These
polymorphisms have little or no effect on the behavior of the
virus in cell culture [13,14] but have profound effects in the
animal [10,14,15].
Despite its pathogenic potential in the laboratory, Py
establishes a silent infection in nature. Virus shed from
persistently infected mothers is transmitted to neonates
which maintain the virus for life without developing tumors
[2,16,17]. In contrast, when inoculated into newborn mice
from a virus-free colony, as little as a few plaque-forming
units of an appropriate virus strain is sufﬁcient to induce the
development of multiple tumors ([8] and unpublished data).
The absence of pathogenic effects in naturally infected mice
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to non– (or low) tumor-inducing strains. It is also possible
that more aggressively replicating strains with potential to
induce tumors or to kill the host outright may be found in
nature, their pathogenic effects offset by protective antibody
delivered through the milk and by rapidly maturing immune
responses of the pups. Differences in host genetic back-
grounds between inbred laboratory mice and feral mice may
also contribute to the different outcomes.
Because laboratory strains of virus have been propagated
and manipulated in culture over many years, it is unclear how
their properties relate to those of naturally occurring virus
strains. This investigation was undertaken to determine the
Vp1 types and pathogenic properties of truly wild-type
strains of Py. To this end, we trapped feral mice at multiple
locations and screened them serologically for Py. Independ-
ent isolates of the virus were established from seropositive
animals. Vp1 coding sequences and biological properties of
these isolates have been compared with prototype laboratory
strains.
Results
Major Determinants of Pathogenicity Lie in the Sialic Acid
Binding Pocket of Vp1
Properties of three prototype ‘‘wild-type’’ laboratory
strains of Py are summarized in Table 1. The abilities of
these strains and of several mutants derived from them to
replicate in newborn mice were previously compared by
whole mouse section hybridization (Figure 1). The small
plaque strain RA shows limited replication and induces few
or no tumors. Tumors that do arise are strictly of
mesenchymal origin and develop after a long latency
approaching one year [8]. The large plaque strain PTA gives
rise to a disseminated infection followed by development of
multiple tumors that are of epithelial as well as mesenchymal
origin. Tumors may be detected grossly as early as 5–6 wk and
grow rapidly, leading to a moribund condition usually within
2–3 mo in essentially 100% of the animals [8]. LID, a large
plaque strain derived from PTA, is virulent [18], killing
neonates within a few weeks due to rapid dissemination and
destruction of vital tissues [9,19]. The LID strain has acquired
virulence without losing tumorigenicity, because mice inocu-
lated with low doses may survive and develop tumors [9].
The different levels of pathogenicity of these three strains
are governed to a large extent by their Vp1 type [9,14]. Amino
acid substitutions at positions 91 and 296 are critical in
determining receptor recognition properties of the virus
[5,9]. The common receptor(s) for all Py strains contain a
terminal sialic acid (NeuNAc) in an a-2,3 linkage to galactose.
Certain gangliosides carrying this linkage have been shown to
be functional receptors, binding and internalizing the virus
and conveying it to the endoplasmic reticulum for disassem-
bly and translocation [20–23]. The sialic acid binds in a
shallow groove of complementary shape on the surface of the
virus with no apparent conformational changes induced in
Vp1 upon binding. Co-crystal structures of whole virus or
recombinant Vp1 pentamers together with sialyloligosac-
charides have been determined at high resolution. These
reveal electrostatic, hydrogen bond, and van der Waals
interactions between side chains of Vp1 and the oligosac-
charide receptor. Substitutions of glycine for glutamic acid at
position 91 and alanine for valine at position 296 have
profound effects, the former in allowing the virus to
discriminate between true receptors and ‘‘pseudoreceptors’’
and the latter in determining binding afﬁnity and ease of
dissociation [5,11,12].
The effects of these substitutions can be rationalized as
follows. The carbohydrate moiety of the receptor is com-
monly found in a trisaccharide [NeuNAc-(a2,3)-Gal-(b1,3)-
GalNAc] in which the GalNAc in the third position may be
linked via an a2,6 linkage to another sialic acid, forming a
branched di-sialic acid chain [NeuNAc-(a2,3)-Gal-(b1,3)-
(NeuNAc-(a2,6)-GalNAc]. Small plaque strains such as RA
bind to both the branched and straight chain oligosacchar-
ides, while large plaque strains bind only to the straight chain
[24,25]. The crystal structures indicate that electrostatic
repulsion and steric interference between the glutamic acid
at position 91 of Vp1 and an a2,6-linked sialic acid would
prevent virus binding to the branched chain oligosaccharide.
For this reason, large plaque strains such as PTA and LID with
Table 1. Determinants of Pathogenicity in the Sialic Acid Binding
Pocket of Vp1
Vp1 Polymorphisms
a Biological and Receptor-
Binding Properties 91 296
G V RA prototype strain. Non-pathogenic: attenuated
spread, few or no tumors; recognition of branched
chain sialic acid ‘‘pseudoreceptors,’’ dictated by 91G.
E V PTA prototype strain. Tumorigenic: efficient
virus spread; failure to recognize ‘‘pseudoreceptors,’’
dictated by 91E.
E A LID prototype strain. Virulent: rapid dissemination
and early death; decreased avidity for receptor,
dictated by 296A.
G A Recombinant strain. Non-pathogenic:
‘‘pseudoreceptor’’ recognition (91G) overrides
virulence (296A).
aAmino acids encoded at positions 91 and 296 are indicated. See also Figure 1.
A, alanine; E, glutamine acid; G, glycine; and V, valine.
doi:10.1371/journal.ppat.0030179.t001
PLoS Pathogens | www.plospathogens.org December 2007 | Volume 3 | Issue 12 | e179 1880
Vp1 Type and Oncogenicity of New Polyoma Isolates
Author Summary
Strains of the mouse polyoma virus adapted to growth in cell culture
vary greatly in their abilities to cause disease. Pathogenicities of
these laboratory strains range from ‘‘attenuated’’ to ‘‘highly
virulent’’ when tested in animals. The biological differences are
based in large part on variations in the outer capsid protein, which
dictate the manner in which the virus recognizes and binds to cell
receptors. In contrast, strains of virus newly isolated from wild mice
are uniform in their receptor-binding properties. Naturally occurring
strains avoid binding to pseudoreceptors, which would severely
limit their ability to spread. At the same time, their avidity of binding
to true receptors is sufficiently strong to avoid rapid dissociation and
potentially lethal spread. They are therefore neither attenuated nor
virulent. The new isolates do, however, retain the ability to induce a
broad spectrum of tumors in the laboratory. These findings
emphasize the importance of neonatal and maternal immune
responses in allowing a potentially highly oncogenic virus to
disseminate without causing disease.glutamic acid at 91 are constrained to bind only the straight
chain receptor. Substitution of glycine for glutamic acid at
this position opens up another pocket able to accommodate
the second (a2,6-linked) NeuNAc. RA and other small plaque
strains are thus able to bind both the branched and the
straight chain oligosaccharides. Because small plaque strains
have broader receptor binding capability and at the same
time are inhibited in replication in the mouse (compare RA
and PTA in Figure 1), the branched chain oligosaccharide is
considered to be a pseudoreceptor, i.e., one that binds virus
without leading to infection and thus retarding virus spread
[5,10]. The polymorphism at position 91 also dictates plaque
size, presumably by affecting release from cell debri and
relative ease of spread in cell monolayers. It also affects
interaction with erythrocyte receptors, altering the pH- and
temperature-dependence of hemagglutination [13].
The valine to alanine substitution at position 296 intro-
duces a subtle alteration in a hydrophobic surface forming
part of the sialic acid binding groove. Valine at this position
(PTA) makes a van der Waals contact with the sialic acid ring,
while the shorter chain alanine (LID) does not. The alanine
substitution thus weakens the hydrophobic interaction with
the receptor [9]. Loss of this interaction is expected to
facilitate dissociation of the virus from cell debri following a
lytic infection. The ability of LID to spread rapidly and
destroy vital tissues underlies its virulent behavior. Site-
directed mutagenesis has conﬁrmed the importance of these
substitutions (Figure 1 and [10]). Thus, PTA-V296A spreads
more rapidly and extensively than PTA and to a degree
similar to LID. It also induces early death in neonatal mice
[10]. Studies of site-directed mutants have also shown that
recognition of branched chain pseudoreceptors exerts a
dominant effect biologically. Introduction of 91G into
virulent or tumorigenic strains results in attenuation of
spread. This is seen by comparing PTA-E91G, PTAV296A-
E91G, and LID-E91G with their respective parental strains
(Figure 1). PTA-E91G has been shown to be less tumorigenic
than PTA, consistent with its reduced ability to spread [10].
Screening of Feral Mice and Isolation of Py
To determine the Vp1 type(s) of Py under natural
conditions, feral mice were trapped and screened serologi-
cally for ones that carried the virus. A total of 71 mice were
trapped alive from 12 locations in and around Boston and as
far away as Cuttyhunk Island, MA, and New York City. Mice
were humanely killed, sera collected, and kidneys frozen for
attempts at virus isolation. Screening for Py was carried out
on the serum from each mouse using a hemagglutination
inhibition (HA-I) assay. Results are shown in Table 2. Using a
cutoff of 160 HA-I for non-speciﬁc inhibition, mice fell into
two groups based on their HA-I titers and the location where
they were trapped. Mice from four locations were uniformly
negative, with HA-I titers ranging from 20 to 160. Mice
trapped at the other eight locations were all positive, with
HA-I titers ranging from 640 to 10,240. Eight locations
yielded multiple mice. Mice from a given location were either
all positive or all negative indicating that whenever present
the virus spreads efﬁciently within each breeding population.
No tumors were noted in either the HA-I–positive or –
negative mice, with one exception, a ﬁbroma, which upon
histological examination appeared not to be typical of Py
tumors. These ﬁndings of efﬁcient spread with no discernible
pathology are consistent with earlier reports on the epidemi-
ology of natural infections by Py [16,26,27].
Figure 1. Effects of Single Amino Acid Replacements in Vp1 on Replication and Spread in Neonatally Infected C3H/BiDa Mice
Whole mouse section hybridizations were carried out one week after virus inoculation (dose of 25310
7 pfu/animal). See Table 1 and text. Reprinted
from [10] with permission from Academic Press.
doi:10.1371/journal.ppat.0030179.g001
Table 2. Serological Tests for Py Virus in Feral Mice
Location
(Number of Mice)
Average HA–I Titer
a
(Range)
Positive MB(11) 1,690 (640–5,120)
Z1(10) 1,630 (640–5,120)
Z2(7) 3,570 (640–10,240)
H(9) 5,260 (1,280–10,240)
N(3) 5,970 (2,560–10,240)
D(2) 2,560 (2,560)
C(1) 5,120
S(1) 10,240
Negative MM(20) 64 (20–160)
LA(5) 40 (20–80)
NC(1) 80
BV(1) 160
aHA–I titers are given as the reciprocal of the highest dilution of serum that gave
complete agglutination of guinea pig erythrocytes at 4 8C.
doi:10.1371/journal.ppat.0030179.t002
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Vp1 Type and Oncogenicity of New Polyoma IsolatesPy was isolated and ampliﬁed from kidney homogenates of
HA-I–positive mice. Primary kidney epithelial cells prepared
from virus-free baby mice were used for ampliﬁcation.
Cytopathic effects typical of Py developed over a period of
7–12 d in every inoculated culture. First-round lysates gave
plaque titers in the range of 10
6–10
7 pfu/ml. These titers were
lower by 1–2 orders of magnitude compared with those of
laboratory-adapted strains. Several isolates were tested and
shown to be neutralized by anti-Vp1 antibody or by sera from
laboratory mice infected by Py (unpublished data). The feral
mouse virus isolates were further ampliﬁed and analyzed by
DNA sequencing of selected regions of the viral genome. Six
isolates from mice trapped at three locations were tested for
their abilities to induce tumors in newborn mice (see further
below).
Vp1 Coding Sequences and Regulatory Regions of Py
Isolates from Feral Mice
One virus isolate from each of the eight locations was
chosen initially for sequence analysis (Figure 2). To determine
the Vp1 types in these isolates, virus was concentrated from
ﬁrst or second passage lysates and analyzed by PCR and
sequencing. A 1083-bp fragment covering 94% of Vp1 coding
sequences was ampliﬁed and puriﬁed from each of the eight
viruses. Internal primers were used to determine sequences
ﬂanking the 91 and 296 coding regions. All eight isolates
encoded glutamic acid at position 91 and valine at 296. An
additional seven viruses were analyzed from different mice
taken from each of the sites where multiple animals were
trapped. These seven isolates also encoded glutamic acid at 91
and valine at 296 in their Vp1. Thus, 15 of 15 isolates from
mice trapped at eight different locations carried the poly-
morphisms found in standard large plaque tumorigenic
laboratory strains represented by PTA as the prototype.
The entire Vp1 coding regions of the original isolates were
sequenced and conﬁrmed to be identical to that of PTA.
Regulatory sequences ﬂanking the replication origins of
the prototype wild-type strains are variable compared with
their highly conserved coding regions [28]. It was therefore of
interest to determine the degree of variation in regulatory
sequences of the new isolates. It should be noted that all three
prototype strains were being propagated in our laboratory
during the course of this investigation with the RA strain
being most widely used. This raises the possibility of
Figure 2. Origin Regions of Three Standard Polyoma Laboratory Strains and Eight Polyoma Isolates from Feral Mice
Amino acids at positions 91 and 296 of Vp1 are shown on the left. The origin regions on the right are denoted schematically as horizontal lines
representing the sequences between the start sites for Vp2 (CAT‹) and the T antigens (ATGﬁ). The PTA sequence on the top is used as a
reference. The bidirectional replication origin (‹ﬁ) and the PvuII and Bgl1 restriction sites are shown as points of reference. The 40–base pair
duplication at the Bgl1 sites in PTA is designated with shaded rectangles. Insertions and deletions are denoted by open boxes and open triangles,
respectively, along with the number of base pairs.
doi:10.1371/journal.ppat.0030179.g002
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virus isolates. To address this concern and to learn more
about the new isolates, crude lysates were concentrated and
used for analysis. The entire non-coding regions between the
ATG of the T antigens on the early side of the replication
origin and the ATG of Vp2 on the late side (ca. 450 bp) were
ampliﬁed and sequenced in one isolate from each of the eight
sites. Results are presented schematically in Figure 2 and the
sequences are given in Figure S1.
Insertions, deletions, and single base changes distinguish
the different isolates. The S and Z2 isolates were identical to
each other but different from all three prototype strains.
Differences in the new isolates were found dispersed
throughout the non-coding regions in both the ‘‘A’’ and
‘‘B’’ enhancers and on the early side of the origin. PTA carries
two copies of a 40-bp sequence around the Bgl1 site, while the
related LID strain carries a single copy [9]. Two of the isolates
(C and H) carried the duplication as found in PTA, and the
other ﬁve (MB, Z1, Z2, D, and S) carried a single copy. Origin
regions of several additional isolates derived from mice
trapped at the same location were sequenced. Sequences for
independent isolates from each of three sites examined were
found to be the same as shown in Figure 2. Of the 15 isolates
examined, only 1 (C) was found to be identical to PTA
throughout the origin region. None matched either RA or
LID. These results rule against contamination and support
the conclusion that the isolates represent new strains.
Tests for Tumor Induction by Py Isolates from Feral Mice
PTA, RA, and LID have been compared for their abilities to
induce tumors following inoculation into newborn mice of
the highly susceptible C3H/BiDa strain [8,9]. PTA induces
multiple tumors in 100% of these animals. Tumors are of
both epithelial and mesenchymal types. RA induces only
mesenchymal tumors and at a much lower frequency and with
longer average latency. The absence of epithelial tumors with
RA is an important feature distinguishing RA from PTA [8].
LID at doses of approximately 10
5 pfu/animal or higher kills
C3H/BiDa within roughly two weeks. At much lower doses,
animals survive and develop a tumor proﬁle similar to that
induced by PTA.
The ﬁnding of a uniform Vp1 type identical to PTA in the
feral mouse isolates makes several predictions about the
biological behavior of the new strains. First, they should
induce tumors at high frequency and these should include
epithelial as well as mesenchymal types. Second, because the
isolates lack the virulence determinant of LID (296A), they
should not cause early deaths ( 3 wk). To test these
predictions, two isolates from each of three locations were
inoculated into newborn C3H/BiDa mice. The results clearly
support the predictions based on the importance of Vp1 type.
All six isolates induced epithelial as well as mesenchymal
tumors (Table 3). There were no early deaths. Latencies of
tumor development, measured as the average age to
necropsy, varied considerably but were longer than with
PTA. The longer latencies are attributable to the lower titers
of the new isolates. Latencies are known to increase as the
titers decrease [8].
Discussion
Py establishes a silent persistent infection in natural
populations of mice, yet behaves in the laboratory as a
powerful oncogenic agent (reviewed in [4]). This discordance
could be explained if naturally occurring virus strains were
attenuated in some manner compared with highly oncogenic
strains used in the laboratory. Variations in the major capsid
protein of Py dictate a wide range of biological properties
upon inoculation into newborn mice, ranging from non-
pathogenic to tumorigenic to virulent. The purpose of the
present investigation was to determine if these variations,
presently known only in laboratory strains of virus, are also
found in nature. Fifteen new isolates of virus were derived
from feral mice trapped at eight different locations. Only a
single type of Vp1 was found, and it matches that of the large
plaque highly oncogenic laboratory strain PTA [8,14]. The
ﬁnding of PTA-like Vp1 sequences in new isolates is not due
to rapid selection during passage in culture, as both LID and
RA are routinely and faithfully passaged under the same
conditions without change in their Vp1s. Six of six of the new
isolates tested proved to be highly tumorigenic with a tissue
tropism similar to that of PTA. Natural selection therefore
results in virus that retains its pathogenic potential. Natural
variants of the virus have adopted a ‘‘middle ground’’ with
Table 3. Tumor Induction by Laboratory Strains and Feral Mouse Isolates of Polyomavirus
Viruses Average Age at Necropsy (Days) Fraction of Animals with Tumor(s)
a
Epithelial Mesenchymal
Lab Strains PTA 82 32/32 15/32
RA 304 0/30 12/30
Wild Mouse Isolates H-4 165 9/12 11/12
H-6 173 12/12 11/12
MB–3 110 8/8 5/8
MB-6 94 6/6 4/6
N-1 175 9/15 12/15
N-3 176 9/9 8/9
aEpithelial tumors arise from mammary glands, thymus, skin, salivary glands; mesenchymal tumors include fibrosarcoma, osteosarcoma, and renal sarcoma. Newborn C3H/BiDa mice (, 24
h) were inoculated with virus intraperitoneally at 12310
5 pfu/animal for feral mouse Py isolates and approximately 10
6–10
7 pfu/animal for laboratory strains of virus PTA and RA. Data
for the laboratory strains PTA and RA are from [8].
doi:10.1371/journal.ppat.0030179.t003
PLoS Pathogens | www.plospathogens.org December 2007 | Volume 3 | Issue 12 | e179 1883
Vp1 Type and Oncogenicity of New Polyoma Isolatesrespect to their common Vp1 type and ability to spread in the
natural host. Their oncogenic potential is effectively offset by
protective maternal antibody and possibly other host or
environmental factors that accompany natural transmission
(reviewed in [4]).
Glutamic acid at position 91 and valine at position 296
deﬁne critical features of this common Vp1. Glutamic acid–
91 is critical for discriminating between true receptors
carrying a terminal unbranched sialic acid and pseudore-
ceptors with branched chain sialic acids [5,11,12]. A glycine at
this position allows binding to pseudoreceptors, leading to
signiﬁcant attenuation of virus spread [10]. No naturally
occurring strains of Py with glycine-91 have been found. The
failure to ﬁnd such strains implies that binding to pseudor-
eceptors leads to an inhibition of virus spread to a degree
that is incompatible with natural transmission. Therefore,
binding to branched chain sialic acids should not be viewed as
a natural means for attenuating the pathogenic potential of
the virus.
Valine at position 296 establishes a hydrophobic contact
with the receptor, decreasing the rate of dissociation and
spread of the virus. Substitution of alanine at this position
results in loss of the hydrophobic contact and a decreased
overall avidity of binding [9]. The magnitude of the change in
avidity has not been determined precisely. However, given
the engagement of multiple capsomeres (each a pentamer of
Vp1) at the cell surface, even a modest decrease in afﬁnity
would be expected to confer a signiﬁcantly lower overall
avidity of virus binding to the cell. The alanine substitution
clearly results in more rapid and extensive virus spread and
results in a lethal infection of newborn mice [9,10]. No
variants with this substitution have been found in nature.
This suggests the importance of control of the rate of virus
dissociation from infected cell debri and subsequent spread
within the newly infected host. Given the importance of
glutamic acid at 91 in allowing efﬁcient spread without
interference from pseudoreceptors, the coupling with valine
as opposed to alanine at 296 would appear to be essential
because the latter would confer a degree of virulence
potentially incompatible with host survival.
Some viruses promote their release and spread through
mechanisms that effectively destroy host cell receptors.
Prominent examples are the neuraminidase of inﬂuenza
viruses and the Vpu and nef proteins of HIV and simian
immunodeﬁciency virus which act directly or indirectly to
destroy cell receptors. For Py and perhaps other viruses that
lack the means to destroy their own receptors, it appears to
be critical that they regulate their receptor-binding proper-
ties within narrow limits. Afﬁnity of binding must be high
enough to promote efﬁcient cell attachment and entry, yet
not so high as to inhibit dissociation from cell debris and
prevent virus spread. At the same time, receptor afﬁnity must
not be so low as to allow rapid dissociation and spread, which
could endanger the life of the host. The properties of Py
strains RA and LID, lying outside these limits, serve to
illustrate the constraints of natural selection.
While Vp1-coding sequences were entirely conserved,
regulatory sequences showed considerable variability among
the new virus isolates. This variability was evident comparing
isolates from different locations. In a limited sampling of
multiple virus isolates from the same location, regulatory
sequences were conserved, indicating relative stability of
virus circulating at a given time within the same host
breeding population. This ﬁnding is consistent with the
epidemiology and natural history of infection in wild mice
([16,26,27] and reviewed in [4]).
The origin and biological signiﬁcance of the variability in
regulatory sequences of the new isolates are not clear.
Sequences at the replication origin per se as well as the
binding sites for the large T antigen are conserved among the
feral mouse isolates and laboratory strains of virus, although
the number of large T binding sites varies. Signaling pathways
from the middle and small T antigens converge on the
enhancer regions at different sites via a number of cellular
factors affecting viral DNA replication as well as tran-
scription [29,30]. Different enhancer sequences play roles in
the host range properties of the virus in cell culture [30–35]
and in the animal [36–38]. Particular features of the tumor
proﬁle are controlled by a 40-bp duplication upstream of the
early promoter [39]. Studies of the related pneumotropic
polyoma virus of mice have provided evidence for incorpo-
ration of host sequences into the viral enhancers [40,41].
Further studies of the new Py isolates and their molecularly
cloned derivatives will be required to determine whether and
to what extent different enhancer sequences may dictate
differences in tissue tropism for replication and induction of
tumors.
Materials and Methods
Trapping and serological testing. Feral mice (Mus musculus) from 12
locations in and around Boston and as far away as Cuttyhunk Island,
MA, and New York City were trapped and recovered alive using
Sherman Traps and mouse chow coated with peanut butter as bait.
Mice were humanely killed, sera collected for serological testing, and
kidneys frozen at 80 8C. One kidney from each animal was sent to
the Laboratory of Comparative Medicine at Yale University School of
Medicine for testing of common mouse pathogens before attempting
virus isolation in our laboratory. Results on all mice were negative for
all agents tested, including: hantavirus; mouse parvovirus; lympho-
cytic choriomeningitis virus; Theiler’s mouse encephalomyelitis virus;
Sendai virus; minute virus of mice; mouse hepatitis virus; ectromeila;
reovirus; and mycoplasma.
Serological testing for Py was performed in our laboratory using a
standard HA-I assay in V-shaped 96-well microtiter plates. Serial 2-
fold dilutions of mouse sera were incubated with an equal volume of
2–4 HA units of wild-type polyoma (PTA strain) for 30 min at 37 8C,
followed by addition of a suspension of guinea pig erythrocytes (2 3
10
7/ml). Further incubation was at 4 8C for a minimum of 6 h. HA-I
titer was scored as the reciprocal of the highest dilution of serum that
prevented agglutination.
Virus isolation. Mice with sera showing HA-I titers of  160 were
judged to be positive and were considered likely carriers of the virus.
Frozen kidneys from these HA-I–positive mice were thawed and
homogenized in 2 ml serum-free Dulbecco’s Modiﬁed Eagle’s
Medium. Aliquots of the homogenates were used to inoculate
primary baby mouse kidney epithelial cells prepared from Py-free
baby ICR mice. Virus lysates from these cultures were titered by
plaque assay on NIH3T3 cells, concentrated by pelleting, and
resuspended for further analysis.
PCR and DNA sequence analysis. Viral DNA was extracted from
crude or concentrated virus. Selected regions of the viral genome
were ampliﬁed by PCR and sequenced. For Vp1, a 1083-bp region
covering most of the Vp1 coding sequence was ﬁrst ampliﬁed [59
GAATATAGCTGAATACACAG39 (sense) and 59 AGGTGCTGGACC
TTGTGACAGGG39 (anti-sense)] and then sequenced using primers 59
AACAGTGAGCCAGAGCCCACCACC39 for the 91 region and 59
GAGGGAGGCCATGGGATAGGG39 for the 296 region. Additional
sequencing was carried out to conﬁrm and extend coverage of the
entire Vp1. The origin regions were ampliﬁed with primers 59
GTACCGCTGTATTCCTAG39 and 59 CATTCTCAGATTG
TATACTTCAG39 giving a fragment of 1061 bp encompassing all of
the non-coding sequences between the ATG of Vp2 on the late side
and the ATG for the T antigens on the early side of the origin.
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Vp1 Type and Oncogenicity of New Polyoma IsolatesSequencing of this amplicon was carried out with primers 59
CTCATTACACCCTCCAAAGTC39 and 59 CATTCTCAGATTG
TATACTTCAG39. Amplicons were sequenced using cycle sequencing
with BigDye v3.1 dideoxy ﬂuorescent terminators and a 3730xL DNA
Analyzer from Applied Biosystems.
Tumor proﬁle studies. Tumor induction studies were carried out
with six of the 15 virus isolates following previously described
procedures [8]. Brieﬂy, newborn C3H/BiDa mice (, 24 h old) were
inoculated with virus intraperitoneally at approximately 10
5 pfu/
animal. Six to 12 animals were used for each virus. Animals were
followed for tumor development grossly and were necropsied when
moribund. Tumors were conﬁrmed by histological examination and
grouped as epithelial or mesenchymal. The former includes tumors
arising from mammary glands, thymus, skin, and salivary glands and
the latter includes ﬁbrosarcoma, osteosarcoma, and renal sarcoma.
Results with the six new isolates are compared with previously
published results for PTA and RA [8].
Supporting Information
Figure S1. Nucleotide Sequences of the Noncoding Regions of
Prototype Laboratory Strains (PTA, RA, and LID) and New Isolates of
Polyoma Viruses (MB, Z1, Z2, H, N, D, C, and S)
The sequences cover the region from the translation start site for Vp2
on the late side (nucleotide 5002; NCBI accession number J02288 for
polyomavirus strain A2) to the translation start site of the T antigens
on the early side (nucleotide 177 in A2). The ori-core sequence
(nucleotides 5276–44); [42] is boxed. ; marks nucleotide 1 in A2. Two
PvuII sites (nucleotides 5130–5135 and 5267–5272 in A2) and one BglI
site (nucleotides 89–99 in A2) are shaded for reference. All sequences
are compared with PTA, which has a 40–base pair duplication on the
early side of the replication origin (nucleotides 71–110 in A2, not
duplicated). Variations from the PTA sequence are shown in red.
Found at doi:10.1371/journal.ppat.0030179.sg001 (28 KB PDF).
Accession Numbers
GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) acces-
sion numbers for sequences of laboratory strains of polyoma virus
are as follows: A2 strain (JO2288), PTA strain (U27812), LID strain
(U27813), and RA strain Vp1 (M34958). Additional sequences for
non-coding and coding regions of RA may be found in [14] and [28].
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